Pacira BioSciences, Inc. PCRX
Regular-session close
After hours · Nov 16, 4:00 PM ET
- YTD
- +40.96%
- 1 year
- +53.41%
- Market cap
- 1.46B
- Revenue (ttm)
- 743.30M
- Profit margin
- 5.08%
- EPS (ttm)
- 0.93
- Shares out
- 39.91M
- P/E ratio
- 39.23
- Forward P/E
- 10.39
- YTD return
- +40.96%
- 1-year return
- +53.41%
- 50-day average
- 31.39
- Volume
- 1.81M
- Avg volume
- 1.32M
- Open
- 36.48
- Previous close
- 36.48
- Day's range
- 36.48 – 36.49
- 52-week range
- 18.80 – 36.67
- Beta
- 0.22
- Analysts
- Hold
- Price target
- 33.57 (-8.0%)
- Earnings date
- Feb 25, 2027
5D 0.00 (0.00%)
Key statistics
- 200-day average
- 25.73
- Enterprise value
- 1.51B
- PEG ratio
- 0.99
- Price / sales
- 1.96
- Price / book
- 2.04
- Revenue growth
- -1.60%
- Free cash flow
- 187.77M
- Total cash
- 295.58M
- Total debt
- 340.28M
- Return on equity
- 5.24%
- Short % of float
- 12.05%
Fundamental scorecard
15 of 25 checks passed on PCRX’s reported financials
15of 25 checks passed
- Value 3 of 5
- Growth 4 of 5
- Profitability 3 of 5
- Financial health 5 of 5
- Dividend 0 of 5
Statements to Sep 30, 2026.
Analyst view
Consensus: hold
- Target (low)
- 25.00
- Target (mean)
- 33.57
- Target (high)
- 36.50
- Strong buy0
- Buy0
- Hold9
- Sell0
- Strong sell0
Next earnings
Feb 25, 2027
Expected Feb 25, 2027. Consensus EPS estimate 0.91.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Feb 25, 2027 | Dec 30, 2026 | 0.80 | — | — | — |
| Nov 5, 2026 | Sep 30, 2026 | 0.752 | 0.72 | -0.03 | -4.26% |
| Aug 4, 2026 | Jun 30, 2026 | 0.646 | 0.73 | +0.08 | +13.00% |
| Apr 30, 2026 | Mar 31, 2026 | 0.61 | 0.60 | -0.01 | -1.64% |
| Feb 26, 2026 | Dec 31, 2025 | 0.85 | 0.57 | -0.28 | -32.94% |
| Nov 6, 2025 | Sep 30, 2025 | 0.65 | 0.70 | +0.05 | +7.69% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 9, 2026 | Truist Securities | down | Buy | Hold |
| Oct 9, 2026 | RBC Capital | main | Sector Perform | Sector Perform |
| Oct 9, 2026 | HC Wainwright & Co. | down | Buy | Neutral |
| Oct 8, 2026 | JP Morgan | up | Underweight | Neutral |
| Oct 8, 2026 | Jefferies | down | Buy | Hold |
| Oct 8, 2026 | Needham | down | Buy | Hold |
About Pacira BioSciences, Inc.
Pacira BioSciences, Inc. engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension for postsurgical pain management; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension indicated for the management of osteoarthritis and knee pain; and iovera system, a non-opioid handheld cryoanalgesia device used to deliver controlled doses of cold temperature to targeted nerves to produce neurolytic block that interrupts the pain-transmitting signals of a peripheral nerve. It also develops PCRX-201, a novel gene therapy vector platform enabling local administration of genetic medicines with the potential to treat large prevalent diseases like osteoarthritis. It has a development and commercialization, and supply agreement with Aratana Therapeutics, Inc. for NOCITA, a bupivacaine liposome injectable suspension product for use in animals. The company was formerly known as Pacira Pharmaceuticals, Inc. and changed its name to Pacira BioSciences, Inc. in April 2019. Pacira BioSciences, Inc. was incorporated in 2006 and is headquartered in Brisbane, California.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Country
- United States
- Website
- pacira.com
News
Ingram Micro Holding Set to Join S&P SmallCap 600 Ingram Micro To Replace Pacira Biosciences In the S&P SmallCap 600 Effective Prior To The Opening Of Trading On Tuesday, November 17
Drug Makers or Biotech Bets: Which ETF Is the Better Buy, State Street’s XPH or First Trust’s FBT? Pacira BioSciences Withdraws 2026 Guidance Pending Proposed Merger With Viatris
Viatris Subsidiary Peach Purchaser Sub Commences Tender Offer To Acquire Pacira Biosciences For $36.50/Shr
Your note
Sign in to keep a note on PCRX — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BREGE LAURA A | Director | Stock Award(Grant) | Jun 9, 2026 | 30,120 |
| CROSS SHAWN M. | Chief Financial Officer | Conversion of Exercise of derivative security | Apr 22, 2026 | 105,341 |
| FROIMSON MARK | Director | Stock Award(Grant) | Jun 9, 2026 | 26,541 |
| GAUGLER DARYL | Chief Operating Officer | Stock Award(Grant) | Dec 30, 2024 | 115,443 |
| KRONENFELD MARK A | Director | Stock Award(Grant) | Jun 10, 2025 | 34,901 |
| LEE FRANK DON | Chief Executive Officer | Stock Award(Grant) | Feb 10, 2026 | 660,831 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Blackrock Inc. | 17.30% | 6,935,801 | 253.02M | Sep 29, 2026 |
| Doma Perpetual Capital Management LLC | 6.93% | 2,777,794 | 101.33M | Sep 29, 2026 |
| Vanguard Portfolio Management LLC | 5.92% | 2,372,291 | 86.54M | Sep 29, 2026 |
| Dimensional Fund Advisors LP | 5.67% | 2,271,610 | 82.87M | Sep 29, 2026 |
| State Street Corporation | 5.35% | 2,145,298 | 78.26M | Sep 29, 2026 |
| Shaw D.E. & Co., Inc. | 4.67% | 1,872,531 | 68.31M | Sep 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| iShares Trust-iShares Core S&P Small-Cap ETF | 5.92% | 2,372,015 | 86.53M | Sep 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 2.99% | 1,198,792 | 43.73M | Jun 29, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 2.55% | 1,023,867 | 37.35M | Sep 29, 2026 |
| American Century ETF Trust-Avantis U.S. Small Cap Value ETF | 2.25% | 901,996 | 32.90M | Sep 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund | 2.14% | 856,213 | 31.23M | Jun 29, 2026 |
| IMPAX FUNDS SERIES TRUST I-Impax Small Cap Fund | 1.87% | 750,027 | 27.36M | Jun 29, 2026 |
